Literature DB >> 26343921

Animal models of Parkinson's disease: An updated overview.

P Gubellini1, P Kachidian2.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder whose etiology, besides a minority of genetic cases, is still largely unknown. Animal models have contributed to elucidate PD etiology and pathogenesis, as well as its cellular and molecular mechanisms, leading to the general hypothesis that this neurological disorder is due to complex interactions between environmental and genetic factors. However, the full understanding of PD is still very far from being achieved, and new potential treatments need to be tested to further improve patients' quality of life and, possibly, slow down the neurodegenerative process. In this context, animal models of PD are required to address all these issues. "Classic" models are based on neurotoxins that selectively target catecholaminergic neurons (such as 6-hydroxydopamine, 1-methyl-1,2,3,6-tetrahydropiridine, agricultural pesticides, etc.), while more recent models employ genetic manipulations that either introduce mutations similar to those find in familial cases of PD (α-synuclein, DJ-1, PINK1, Parkin, etc.) or selectively disrupt nigrostriatal neurons (MitoPark, Pitx3, Nurr1, etc.). Each one of these models has its own advantages and limitations, thus some are better suited for studying PD pathogenesis, while others are more pertinent to test therapeutic treatments. Here, we provide a critical and updated review of the most used PD models.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Corps de Lewy; Dopamine; Lewy bodies; Neurodegeneration; Neurodégénérescence; Nigrostriatal; Pathologie progressive; Progressive disease; Voie nigrostriée

Mesh:

Year:  2015        PMID: 26343921     DOI: 10.1016/j.neurol.2015.07.011

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  22 in total

Review 1.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

2.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

3.  Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.

Authors:  Muhammet Ay; Jie Luo; Monica Langley; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Neurochem       Date:  2017-05-09       Impact factor: 5.372

Review 4.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

5.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02

6.  Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease.

Authors:  Eva Martínez-Pinilla; David Aguinaga; Gemma Navarro; Alberto J Rico; Julen Oyarzábal; Juan A Sánchez-Arias; José Luis Lanciego; Rafael Franco
Journal:  Mol Neurobiol       Date:  2019-01-28       Impact factor: 5.590

7.  Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease.

Authors:  Seyma Bahdoudi; Ikram Ghouili; Mansour Hmiden; Jean-Luc do Rego; Benjamin Lefranc; Jérôme Leprince; Julien Chuquet; Jean-Claude do Rego; Ann-Britt Marcher; Susanne Mandrup; Hubert Vaudry; Marie-Christine Tonon; Mohamed Amri; Olfa Masmoudi-Kouki; David Vaudry
Journal:  Cell Mol Life Sci       Date:  2017-12-20       Impact factor: 9.261

8.  Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats.

Authors:  Shakshi Sharma; Khadga Raj; Shamsher Singh
Journal:  Neurotox Res       Date:  2019-10-25       Impact factor: 3.911

Review 9.  Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.

Authors:  Upasana Ganguly; Sukhpal Singh; Soumya Pal; Suvarna Prasad; Bimal K Agrawal; Reena V Saini; Sasanka Chakrabarti
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

Review 10.  Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease.

Authors:  Daniela Maria Vogt Weisenhorn; Florian Giesert; Wolfgang Wurst
Journal:  J Neurochem       Date:  2016-06-27       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.